{
  "id": 18334273,
  "title": "Shattuck Labs stock price target maintained at $18 by Raymond James",
  "url": "https://urgent.news/2026/11/05/shattuck-labs-stock-price-target-maintained-at-18-by-raymond-james",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-05T16:08:44.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/shattuck-labs-stock-price-target-maintained-at-18-by-raymond-james-93CH-5005162"
  },
  "original_language": "en",
  "account": "Raymond James has retained its strong buy rating and price target of $18.00 for Shattuck Labs (NASDAQ:STTK) shares, despite the stock's recent decline of nearly 10% over the past week. The company's shares have delivered a remarkable 152% return over the past year, and Shattuck Labs reported solid third-quarter 2026 financial results with more cash than debt on its balance sheet. Analysts anticipate a Phase 2 study for SL-325 in Crohn's disease and a planned Phase 2 study for hidradenitis suppurativa to begin in the fourth quarter of 2026. Shattuck Labs also initiated preclinical trials for SL-846, a DR3 x IL-23R bispecific, with initial Phase 1 data expected in 2027. Analysts highlight Shattuck Labs' potential in the pharmaceutical market, with several firms updating their coverage and price targets for the company's shares.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}